|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5MC1 |
Gene summary for ATP5MC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5MC1 | Gene ID | 516 |
| Gene name | ATP synthase membrane subunit c locus 1 | |
| Gene Alias | ATP5A | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P05496 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 516 | ATP5MC1 | GSM4909281 | Human | Breast | IDC | 5.71e-12 | 4.63e-01 | 0.21 |
| 516 | ATP5MC1 | GSM4909282 | Human | Breast | IDC | 4.05e-09 | 4.53e-01 | -0.0288 |
| 516 | ATP5MC1 | GSM4909285 | Human | Breast | IDC | 2.93e-24 | 5.34e-01 | 0.21 |
| 516 | ATP5MC1 | GSM4909286 | Human | Breast | IDC | 1.37e-37 | 6.97e-01 | 0.1081 |
| 516 | ATP5MC1 | GSM4909287 | Human | Breast | IDC | 6.18e-19 | 5.63e-01 | 0.2057 |
| 516 | ATP5MC1 | GSM4909288 | Human | Breast | IDC | 1.05e-05 | 3.89e-01 | 0.0988 |
| 516 | ATP5MC1 | GSM4909293 | Human | Breast | IDC | 1.67e-09 | 1.94e-01 | 0.1581 |
| 516 | ATP5MC1 | GSM4909294 | Human | Breast | IDC | 3.36e-04 | 4.32e-01 | 0.2022 |
| 516 | ATP5MC1 | GSM4909295 | Human | Breast | IDC | 5.77e-03 | 2.57e-01 | 0.0898 |
| 516 | ATP5MC1 | GSM4909297 | Human | Breast | IDC | 6.82e-06 | -3.91e-02 | 0.1517 |
| 516 | ATP5MC1 | GSM4909298 | Human | Breast | IDC | 9.36e-18 | 5.14e-01 | 0.1551 |
| 516 | ATP5MC1 | GSM4909300 | Human | Breast | IDC | 2.82e-03 | 3.31e-01 | 0.0334 |
| 516 | ATP5MC1 | GSM4909301 | Human | Breast | IDC | 2.21e-02 | 3.51e-01 | 0.1577 |
| 516 | ATP5MC1 | GSM4909302 | Human | Breast | IDC | 1.23e-04 | 2.53e-01 | 0.1545 |
| 516 | ATP5MC1 | GSM4909303 | Human | Breast | IDC | 2.19e-03 | 3.55e-01 | 0.0438 |
| 516 | ATP5MC1 | GSM4909304 | Human | Breast | IDC | 8.64e-03 | 2.24e-01 | 0.1636 |
| 516 | ATP5MC1 | GSM4909305 | Human | Breast | IDC | 4.04e-08 | 2.90e-01 | 0.0436 |
| 516 | ATP5MC1 | GSM4909306 | Human | Breast | IDC | 2.44e-04 | 3.73e-01 | 0.1564 |
| 516 | ATP5MC1 | GSM4909307 | Human | Breast | IDC | 2.44e-21 | 6.56e-01 | 0.1569 |
| 516 | ATP5MC1 | GSM4909308 | Human | Breast | IDC | 4.07e-30 | 6.11e-01 | 0.158 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00725224 | Stomach | GC | purine-containing compound biosynthetic process | 28/1159 | 200/18723 | 4.36e-05 | 1.06e-03 | 28 |
| GO:00091653 | Stomach | GC | nucleotide biosynthetic process | 31/1159 | 254/18723 | 2.35e-04 | 3.95e-03 | 31 |
| GO:19012933 | Stomach | GC | nucleoside phosphate biosynthetic process | 31/1159 | 256/18723 | 2.70e-04 | 4.44e-03 | 31 |
| GO:004603411 | Stomach | CAG with IM | ATP metabolic process | 72/1050 | 277/18723 | 6.46e-29 | 1.72e-25 | 72 |
| GO:001598511 | Stomach | CAG with IM | energy coupled proton transport, down electrochemical gradient | 16/1050 | 26/18723 | 2.67e-14 | 1.30e-11 | 16 |
| GO:001598611 | Stomach | CAG with IM | ATP synthesis coupled proton transport | 16/1050 | 26/18723 | 2.67e-14 | 1.30e-11 | 16 |
| GO:190260011 | Stomach | CAG with IM | proton transmembrane transport | 34/1050 | 157/18723 | 7.15e-12 | 2.38e-09 | 34 |
| GO:000914411 | Stomach | CAG with IM | purine nucleoside triphosphate metabolic process | 25/1050 | 88/18723 | 8.00e-12 | 2.40e-09 | 25 |
| GO:000920611 | Stomach | CAG with IM | purine ribonucleoside triphosphate biosynthetic process | 22/1050 | 68/18723 | 8.10e-12 | 2.40e-09 | 22 |
| GO:000920511 | Stomach | CAG with IM | purine ribonucleoside triphosphate metabolic process | 24/1050 | 82/18723 | 1.03e-11 | 2.76e-09 | 24 |
| GO:000914511 | Stomach | CAG with IM | purine nucleoside triphosphate biosynthetic process | 22/1050 | 69/18723 | 1.13e-11 | 2.86e-09 | 22 |
| GO:000675411 | Stomach | CAG with IM | ATP biosynthetic process | 20/1050 | 57/18723 | 1.32e-11 | 3.14e-09 | 20 |
| GO:000920111 | Stomach | CAG with IM | ribonucleoside triphosphate biosynthetic process | 22/1050 | 74/18723 | 5.34e-11 | 1.09e-08 | 22 |
| GO:000919911 | Stomach | CAG with IM | ribonucleoside triphosphate metabolic process | 24/1050 | 89/18723 | 7.02e-11 | 1.34e-08 | 24 |
| GO:000914211 | Stomach | CAG with IM | nucleoside triphosphate biosynthetic process | 23/1050 | 85/18723 | 1.62e-10 | 2.98e-08 | 23 |
| GO:000914111 | Stomach | CAG with IM | nucleoside triphosphate metabolic process | 26/1050 | 112/18723 | 4.23e-10 | 6.83e-08 | 26 |
| GO:000915011 | Stomach | CAG with IM | purine ribonucleotide metabolic process | 48/1050 | 368/18723 | 4.36e-08 | 3.32e-06 | 48 |
| GO:000616311 | Stomach | CAG with IM | purine nucleotide metabolic process | 50/1050 | 396/18723 | 6.52e-08 | 4.63e-06 | 50 |
| GO:000925911 | Stomach | CAG with IM | ribonucleotide metabolic process | 48/1050 | 385/18723 | 1.76e-07 | 1.16e-05 | 48 |
| GO:000915211 | Stomach | CAG with IM | purine ribonucleotide biosynthetic process | 28/1050 | 169/18723 | 2.35e-07 | 1.51e-05 | 28 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |